Non-Alcoholic Steatohepatitis Biomarkers Market Research Report - Forecast till 2027

Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Report: Information by Disease Outlook, Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Others), End User (Pharmaceutical Companies and CROs, Others) - Forecast till 2027

ID: MRFR/HC/6512-CR | June 2019 | Region: Global | 111 Pages         

1 Executive Summary

1.1 Market Attractiveness Analysis 16

2 Market Introduction

2.1 Definition 18

2.2 Scope Of The Study 18

2.3 Assumptions 18

2.4 Market Structure 18

3 Research Methodology

3.1 Research Process 19

3.2 Primary Research 20

3.3 Secondary Research 21

3.4 Market Size Estimation 22

3.5 Forecast Model 22

4 Market Dynamics

4.1 Overview 23

4.2 Drivers 24

4.2.1 Increasing Prevalence Of Diabetes And Obesity 24

4.2.2 Growing Demand For Non-Invasive Tests 24

4.2.3 Rising Public And Private Sector Initiatives To Increase Awareness About NASH 24

4.3 Restraints 25

4.3.1 Stringent Regulatory Scenario 25

4.4 Opportunities 25

4.4.1 Growing Mergers And Acquisitions To Develop Novel Biomarkers 25

5 Market Factor Analysis

5.1 Value Chain Analysis 26

5.1.1 R&D And Designing 26

5.1.2 Manufacturing 26

5.1.3 Distribution & Sales 26

5.1.4 Post-Sales Review 27

5.2 Porter’s Five Forces Model 27

5.2.1 Bargaining Power Of Suppliers 27

5.2.2 Bargaining Power Of Buyers 28

5.2.3 Threat Of New Entrants 28

5.2.4 Threat Of Substitutes 28

5.2.5 Intensity Of Rivalry 28

5.3 Pipeline Analysis 28

5.3.1 Overview 28

5.3.2 Recent Developments In Product Pipeline 29

5.4 Regulatory Landscape 29

5.5 Non-Alcoholic Steatohepatitis Biomarkers: Disease Cause Outlook 30

5.5.1 Overview 30

5.5.2 Obesity 30

5.5.3 Type 2 Diabetes 30

5.5.4 Hyperlipidemia 31

5.5.5 Hypertension 31

5.5.6 Metabolic Syndrome (MetS) 31

6 Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

6.1 Overview 32

6.2 Serum Biomarkers 34

6.3 Hepatic Fibrosis Biomarkers 35

6.4 Apoptosis Biomarkers 37

6.5 Oxidative Stress Biomarkers 38

6.6 Others 38

7 Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

7.1 Overview 39

7.2 Pharmaceutical Companies And CROs 41

7.3 Research Institutes And Academic Centers 42

7.4 Diagnostic Centers 43

7.5 Hospitals & Clinics 44

8 Global Non-Alcoholic Steatohepatitis Biomarkers Market, By Region

8.1 Overview 45

8.2 Americas 47

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.2.1 North America 49

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.2.1.1 US 51

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.2.1.2 Canada 52

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.2.2 Latin America 53

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3 Europe 55

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1 Western Europe 58

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.1 UK 60

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.2 Germany 61

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.3 France 62

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.4 Italy 63

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.5 Spain 64

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.6 Rest Of Western Europe 65

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.2 Eastern Europe 66

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4 Asia-Pacific 67

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.1 Japan 69

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.2 China 70

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.3 India 71

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.4 Australia 72

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.5 South Korea 73

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.6 Rest Of Asia-Pacific 74

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.5 Middle East & Africa 76

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.5.1 Middle East 78

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.5.2 Africa 79

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

9 Competitive Landscape

9.1 Overview 81

9.2 Key Development Analysis 82

10 Company Profiles

10.1 BioPredictive 83

10.1.1 Company Overview 83

10.1.2 Financial Overview 83

10.1.3 Products/Services Offered 83

10.1.4 Key Developments 83

10.1.5 SWOT Analysis 83

10.1.6 Key Strategies 84

10.2 Celerion 85

10.2.1 Company Overview 85

10.2.2 Financial Overview 85

10.2.3 Products/Services Offered 85

10.2.4 Key Developments 85

10.2.5 SWOT Analysis 85

10.2.6 Key Strategies 85

10.3 Cisbio 86

10.3.1 Company Overview 86

10.3.2 Financial Overview 86

10.3.3 Products/Services Offered 87

10.3.4 Key Developments 87

10.3.5 SWOT Analysis 88

10.3.6 Key Strategies 88

10.4 Echosens 89

10.4.1 Company Overview 89

10.4.2 Financial Overview 89

10.4.3 Products/Services Offered 89

10.4.4 Key Developments 89

10.4.5 SWOT Analysis 90

10.4.6 Key Strategies 90

10.5 Enterome 91

10.5.1 Company Overview 91

10.5.2 Financial Overview 91

10.5.3 Products/Services Offered 91

10.5.4 Key Developments 91

10.5.5 SWOT Analysis 91

10.5.6 Key Strategies 91

10.6 GENFIT 92

10.6.1 Company Overview 92

10.6.2 Financial Overview 92

10.6.3 Products/Services Offered 92

10.6.4 Key Developments 92

10.6.5 SWOT Analysis 93

10.6.6 Key Strategies 93

10.7 Laboratory Corporation Of America Holdings 94

10.7.1 Company Overview 94

10.7.2 Financial Overview 94

10.7.3 Products/Services Offered 95

10.7.4 Key Developments 95

10.7.5 SWOT Analysis 95

10.7.6 Key Strategies 95

10.8 NGM Biopharmaceuticals 96

10.8.1 Company Overview 96

10.8.2 Financial Overview 96

10.8.3 Products/Services Offered 96

10.8.4 Key Developments 96

10.8.5 SWOT Analysis 96

10.8.6 Key Strategies 96

10.9 One Way Liver, SL 97

10.9.1 Company Overview 97

10.9.2 Financial Overview 97

10.9.3 Products/Services Offered 97

10.9.4 Key Developments 97

10.9.5 SWOT Analysis 97

10.9.6 Key Strategies 97

10.10 Pacific Biomarkers 98

10.10.1 Company Overview 98

10.10.2 Financial Overview 98

10.10.3 Products/Services Offered 98

10.10.4 Key Developments 98

10.10.5 SWOT Analysis 99

10.10.6 Key Strategies 99

10.11 Prometheus Laboratories Inc. 100

10.11.1 Company Overview 100

10.11.2 Financial Overview 100

10.11.3 Products/Services Offered 101

10.11.4 Key Developments 101

10.11.5 SWOT Analysis 101

10.11.6 Key Strategies 101

10.12 Perspectrum Diagnostics Ltd 102

10.12.1 Company Overview 102

10.12.2 Financial Overview 102

10.12.3 Products/Services Offered 102

10.12.4 Key Developments 102

10.12.5 SWOT Analysis 102

10.12.6 Key Strategies 102

10.13 Quest Diagnostics 103

10.13.1 Company Overview 103

10.13.2 Financial Overview 103

10.13.3 Products/Services Offered 104

10.13.4 Key Developments 104

10.13.5 SWOT Analysis 104

10.13.6 Key Strategies 104

10.14 Regulus Therapeutics, Inc. 105

10.14.1 Company Overview 105

10.14.2 Financial Overview 105

10.14.3 Products/Services Offered 105

10.14.4 Key Developments 105

10.14.5 SWOT Analysis 106

10.14.6 Key Strategies 106

10.15 Siemens Healthineers 107

10.15.1 Company Overview 107

10.15.2 Financial Overview 107

10.15.3 Products/Services Offered 108

10.15.4 Key Developments 108

10.15.5 SWOT Analysis 108

10.15.6 Key Strategies 108

10.16 Shenzhen New Industries Biomedical Engineering Co., Ltd 109

10.16.1 Company Overview 109

10.16.2 Financial Overview 109

10.16.3 Products/Services Offered 109

10.16.4 Key Developments 109

10.16.5 SWOT Analysis 109

10.16.6 Key Strategies 109

10.17 Xeptagen SpA 110

10.17.1 Company Overview 110

10.17.2 Financial Overview 110

10.17.3 Products/Services Offered 110

10.17.4 Key Developments 110

10.17.5 SWOT Analysis 110

10.17.6 Key Strategies 110

11 Appendix

11.1 References 111

11.2 Related Reports 111

12 List Of Tables

TABLE 1 NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET: PIPELINE ANALYSIS 28

TABLE 2 NAFLD ASSOCIATED DISEASE CONDITIONS 30

TABLE 3 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 33

TABLE 4 GLOBAL NASH BIOMARKERS MARKET FOR SERUM BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 5 CLASSIFICATION OF LIVER FIBROSIS BIOMARKERS 35

TABLE 6 GLOBAL NASH BIOMARKERS MARKET FOR HEPATIC FIBROSIS BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 7 GLOBAL NASH BIOMARKERS MARKET FOR APOPTOSIS BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 8 GLOBAL NASH BIOMARKERS MARKET FOR OXIDATIVE STRESS BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 9 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 40

TABLE 10 GLOBAL NASH BIOMARKERS MARKET FOR PHARMACEUTICAL COMPANIES AND CRO, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 11 GLOBAL NASH BIOMARKERS MARKET FOR RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY REGION,

2020–2027 (USD MILLION) 42

TABLE 12 GLOBAL NASH BIOMARKERS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 13 GLOBAL NASH BIOMARKERS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 14 GLOBAL NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 15 AMERICAS: NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 48

TABLE 16 AMERICAS: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 48

TABLE 17 AMERICAS: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 49

TABLE 18 NORTH AMERICA: NASH BIOMARKERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 50

TABLE 19 NORTH AMERICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 50

TABLE 20 NORTH AMERICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 51

TABLE 21 US: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 22 US: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 52

TABLE 23 CANADA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 24 CANADA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 53

TABLE 25 LATIN AMERICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 26 LATIN AMERICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 54

TABLE 27 EUROPE: NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 56

TABLE 28 EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 29 EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 57

TABLE 30 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 58

TABLE 31 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 32 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 59

TABLE 33 UK: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 34 UK: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 35 GERMANY: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 36 GERMANY: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 61

TABLE 37 FRANCE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 38 FRANCE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 62

TABLE 39 ITALY: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 40 ITALY: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 41 SPAIN: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 42 SPAIN: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 64

TABLE 43 REST OF WESTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 44 REST OF WESTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 65

TABLE 45 EASTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 46 EASTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 66

TABLE 47 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 68

TABLE 48 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 49 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 69

TABLE 50 JAPAN: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 51 JAPAN: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 70

TABLE 52 CHINA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 53 CHINA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 71

TABLE 54 INDIA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 55 INDIA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 72

TABLE 56 AUSTRALIA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 57 AUSTRALIA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 73

TABLE 58 SOUTH KOREA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 59 SOUTH KOREA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 74

TABLE 60 REST OF ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 61 REST OF ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 75

TABLE 62 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 77

TABLE 63 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 64 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 78

TABLE 65 MIDDLE EAST: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 66 MIDDLE EAST: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 79

TABLE 67 AFRICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 68 AFRICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 80

TABLE 69 TOP MANUFACTURERS IN THE GLOBAL NASH BIOMARKERS MARKET 81

13 List Of Figures

FIGURE 1 MARKET SYNOPSIS 15

FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL NASH BIOMARKERS MARKET 16

FIGURE 3 GLOBAL NASH BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%) 16

FIGURE 4 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 17

FIGURE 5 GLOBAL NASH BIOMARKERS MARKET SHARE, BY END USER, 2020 (%) 17

FIGURE 6 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 17

FIGURE 7 GLOBAL NASH BIOMARKERS MARKET: MARKET STRUCTURE 18

FIGURE 8 RESEARCH PROCESS OF MRFR 19

FIGURE 9 TOP-DOWN & BOTTOM-UP APPROACH 22

FIGURE 10 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 23

FIGURE 11 VALUE CHAIN: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 26

FIGURE 12 PORTER’S FIVE FORCES ANALYSIS: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 27

FIGURE 13 GLOBAL NASH BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%) 32

FIGURE 14 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 33

FIGURE 15 GLOBAL NASH BIOMARKERS MARKET SHARE, BY END USER, 2020 (%) 39

FIGURE 16 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 40

FIGURE 17 GLOBAL NASH BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) 45

FIGURE 18 GLOBAL NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 46

FIGURE 19 AMERICAS: NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 47

FIGURE 20 NORTH AMERICA: NASH BIOMARKERS MARKET, BY COUNTRY, 2020 AND 2027 49

FIGURE 21 EUROPE: NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 55

FIGURE 22 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY COUNTRY, 2020 AND 2027 58

FIGURE 23 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY COUNTRY, 2020 AND 2027 67

FIGURE 24 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 76

FIGURE 25 GLOBAL NASH BIOMARKERS MARKET: COMPETITIVE LANDSCAPE 82

Non Alcoholic Steatohepatitis Biomarkers Market Speak to Analyst Request a Free Sample

Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis


The Non-Alcoholic Steatohepatitis Biomarkers Market is a rapidly growing market. NASH biomarkers are used for easy detection of non-alcoholic steatohepatitis (NASH) which is an advanced form of fatty liver disease. Many liver diseases, especially NASH, are very difficult to detect and diagnose at an early stage without invasive surgeries which generate the need for biomarkers. 


About 25 % of the global adult population suffers from Non-alcoholic fatty liver disease (NAFLD) and Non-Alcoholic Steatohepatitis ( NASH) is the advanced form of NFLD. It is characterized by the presence of excessive fat around the liver. The change in lifestyle of people and increasing reliance on fat-rich food are the major cause of NAFLD. The Non-Alcoholic Steatohepatitis Biomarkers Market is expected to grow at a Compound Annual Growth Rate ( CAGR ) of 20.92% over the current forecast period. 


The NASH biomarkers are essential in detecting chronic non-alcoholic fatty liver disease (NAFLD) in an early stage. This technique makes use of certain bio-molecules to detect the disorders. Thus it doesn't require an invasive surgery which is the only other option. The Non-Alcoholic Steatohepatitis Biomarkers Market value is estimated to be worth USD 1,960.4 million by the end of the current forecast period in 2024.  


Covid 19 Analysis 


Covid 19 had a negative impact on the Non-Alcoholic Steatohepatitis Biomarkers Market growth. Restrictions on travel and the movement of goods caused widespread disruptions in the supply chain. Therefore, there was a shortage of drugs and medical kits in the market for few peak months. 


Moreover, temporary closure of production units to curb the virus spread also resulted in less production and layoff of the working force. Furthermore, Owing to travel restrictions, fewer patients were visiting the diagnostic centers, causing a slump in demand too. However, the market has shown rapid recovery in the post covid period and is likely to exceed the previous growth rate soon. 


Market Dynamics


Drivers


The rising prevalence of chronic liver diseases such as NASH and the need for their early detection and diagnosis is the major growth driving factor. There is no single reliable non-invasive method to detect NAFLD, there are huge prospects for the growth of the Non-Alcoholic Steatohepatitis Biomarkers Market. Therefore, the rising demand for non-invasive diagnosis techniques is another major growth driver. The other diagnostic tests such as liver biopsy are invasive and expensive so are not patient-friendly. 


The increasing obese population and unhealthy food habits are creating a favorable environment for the development of liver disease. Therefore, the rising incidence of chronic liver disease is expected to fuel the market demand for NASH biomarkers over the forecast period.  The ongoing research activities in this sector are likely to sustain the market growth.  


Restraints


The side effects of Non-Alcoholic Steatohepatitis ( NASH) drugs and therapeutics are a potential growth restraining factor. Moreover, stringent regulations for biomarkers approval by regulatory bodies such as FDA is hindering market growth. Furthermore, the lack of advanced testing methods to detect NAFLD is hampering the growth of the Non-Alcoholic Steatohepatitis Biomarkers Market.


Technology Analysis


Non-Alcoholic Steatohepatitis Biomarkers are efficient tools to detect chronic liver diseases at an early stage. Currently, there are no other tests approved for diagnosing Nonalcoholic steatohepatitis except surgery. The liver biopsy is the only alternative reliable method but requires invasive surgery.    


Nonalcoholic steatohepatitis (NASH) is the active form of Nonalcoholic fatty liver disease (NAFLD) with hepatic necroinflammation and faster fibrosis progression. It is the most common chronic liver disease worldwide. The disease occurs due to the buildup of fat in the liver which causes inflammation in the liver and ultimately damages liver cells. 


This testing relies upon serum biomarkers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), etc, hormones, proteins, and other new age biomarkers. This is a non-invasive method and along with other imaging techniques is used to detect the manifestation and progress of NAFLD.  


Study Objectives


This report aims to provide a complete overview of the Non-Alcoholic Steatohepatitis Biomarkers market. The specific objectives of this market report are given below: 


●     To provide a complete overview of the Non-Alcoholic Steatohepatitis Biomarkers market.


●     To analyze and forecast the Non-Alcoholic Steatohepatitis Biomarkers market in terms of value and volume.


●     To provide information about the impact of covid 19 on the market.


●     To identify the problems and prospects of the Non-Alcoholic Steatohepatitis Biomarkers market


●     To give details about the technological know-how of the NASH biomarkers.


●     To provide complete information about the regional markets and potentially growing segments.


●     To identify the key players of the Non-Alcoholic Steatohepatitis Biomarkers industry. 


Segment Analysis 


Segmentation of Non-Alcoholic Steatohepatitis Biomarkers market,


By Type 


●     Hepatic Fibrosis Biomarkers


●     Serum Biomarkers


●     Oxidative Stress Biomarkers


●     Apoptosis Biomarkers


●     Others 


Serum biomarkers are effective and the most widely used NASH diagnosing tool, therefore, occupies a greater market share. It can detect and differentiate between simple steatosis and NASH which offers market advantages. Introductions of new markers such as apolipoprotein A1, apolipoprotein B, leptin, adiponectin, free fatty acids, ghrelin, and tumor necrosis factor-alpha will further propel the market growth. 


Segmentation of Non-Alcoholic Steatohepatitis Biomarkers market,


By end-user 


●     Research Institutes and Academics


●     Diagnostic Centres


●     Pharmaceutical Companies and CROs


●     Hospitals and Clinics


●     Others 


The pharmaceutical companies and CROs lead the end-user segment. There is a high demand for non-invasive diagnostic tools to detect chronic liver disease which is driving the market growth. The rising prevalence of liver disorders and so the demand for pharmaceutical drugs is the growth-promoting factor for this segment.   


Regional Analysis


The different regional markets for the Non-Alcoholic Steatohepatitis Biomarkers market are: 


●     North America


β—‹     US


β—‹     Canada 


●     Latin America


β—‹     Mexico


β—‹     Brazil 


●     Europe


β—‹     UK


β—‹     Germany


β—‹     France


β—‹     Italy


β—‹     Spain


β—‹     Rest of Europe 


●     Asia-Pacific


β—‹     China


β—‹     India


β—‹     Japan


β—‹     Australia & New Zealand


β—‹     Rest of Asia-Pacific 


●     Rest of the world ( RoW )


β—‹     The Middle East


β—‹     Africa. 


The Asia Pacific is the fastest growing regional market for Non-Alcoholic Steatohepatitis Biomarkers. Rapidly developing health infrastructure and pharmaceutical industry accounts for the high market growth. Moreover, a higher prevalence of Non-Alcoholic Steatohepatitis (NASH) and other liver diseases are the major demand generating factors for Non-Alcoholic Steatohepatitis Biomarkers in this region. Furthermore, rising awareness about newer treatment and diagnosis technologies with the increase in literacy rate will boost the market growth further. 


The North American segment holds the largest market share in the global NASH biomarkers market. The growing incidence of chronic diseases such as NAFLD and diabetes is the major market driving force. Moreover, the presence of better healthcare infrastructure sustains the demand for NASH biomarkers. 


Europe with its growing obese population and high disposable income generates high demand for NASH biomarkers. Moreover, good health infrastructure and research facilities are to further boost the market growth in this region.  Latin America,  the Middle East Segment, and Africa are also witnessing growth in the demand for biomarkers.  


Competitive Landscape 


The major global companies playing a key role in the Non-Alcoholic Steatohepatitis Biomarkers market are :


●     Perspectum Diagnostics Ltd.


●     Shenzhen New Industries Biomedical Engineering Co Ltd


●     One Way Liver SL


●     BioPredictive


●     Cisbio


●     Celerion


●     Enterome


●     Echosens


●     GENFIT


●     NGM Biopharmaceuticals


●     Laboratory Corporation of America Holdings


●     Pacific Biomarkers


●     Quest Diagnostics Ltd


●     Prometheus Laboratories Inc


●     Regulus Therapeutics Inc.


●     Xeptagen SpA


●     Boehringer Ingelheim GmbH Inc.


●     Bristol-Myers Squibb


●     AstraZeneca


●     Pfizer Inc. 


Recent Developments


In November 2020, Novo Nordisk, a leading global healthcare company acquired Emisphere Technology, A US-based pharmaceutical company for USD 1.3 billion. This acquisition will benefit Novo Nordisk from Emisphere's drug delivery technology for chronic diseases like liver disorders and diabetes.  


Intended Audience


This report will be beneficial for every stakeholder of the Non-Alcoholic Steatohepatitis Biomarkers market such as :


●     Manufacturers of NASH biomarker-based diagnostic tools


●     Medical Research and Development Institutes


●     End-user Industries


●     Patients 


Report Overview


This report provides an in-depth analysis of the Non-Alcoholic Steatohepatitis Biomarkers market in terms of current value and future forecast. We have also highlighted the problems and prospects of the given market. Moreover, the technological analysis section gives details about the know-how of the product. Furthermore, this report contains a detailed analysis of every segment of the given market for the current forecast period. This report has also highlighted the key players and the current developments in the Non-Alcoholic Steatohepatitis Biomarkers market. 



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Among all the different segments, Serum biomarkers hold the largest market share of non-alcoholic steatohepatitis biomarkers with more than 32.3% due to major benefits like understanding NASH from simple steatosis that makes the outcomes efficient. With these benefits, the need of doing liver biopsy has reduced and increased the growth of this market.

Major key players of the non-alcoholic steatohepatitis biomarkers market are AstraZeneca, GENFIT, Bristol-Myers Squibb, Boehringer Ingelheim GmbH Inc., Gilead, Novartis, Pfizer Inc., Quest Diagnostics, Siemens Healthineers, Xeptagen SPA, Prometheus Laboratories Inc, Laboratory Corporation of America Holdings, One way Liver SL, NGM Biopharmaceuticals, Echosens, BioPredictive, Cisbio, Celerion, Enterome, Shenzhen New Industries Biomedical Engineering Co. Ltd., and others. Many new companies are entering the non-alcoholic steatohepatitis biomarkers market with new strategies and products.

The global non-alcoholic steatohepatitis biomarkers market is expected to grow more than 2.20 billion in the forecast period. The CAGR is projected to be around 30.4% with the increasing chronic liver condition cases.